Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.